710
Views
0
CrossRef citations to date
0
Altmetric
Cardiology & Cardiovascular Disorders

Risk stratification algorithm for clinical outcomes in anemic patients undergoing percutaneous coronary intervention

, , , , , , , & show all
Article: 2249200 | Received 19 Jun 2023, Accepted 11 Aug 2023, Published online: 24 Aug 2023

References

  • Chaparro CM, Suchdev PS. Anemia epidemiology, pathophysiology, and etiology in low- and Middle-income countries. Ann N Y Acad Sci. 2019;1450(1):1–14.
  • Marton I, Agócs S, Babik B. Epidemiology of anemia. Orv Hetil. 2020;161(37):1569–1573. doi: 10.1556/650.2020.31916.
  • Stucchi M, Cantoni S, Piccinelli E, et al. Anemia and acute coronary syndrome: current perspectives. Vasc Health Risk Manag. 2018;14:109–118. doi: 10.2147/VHRM.S140951.
  • Sarnak MJ, Tighiouart H, Manjunath G, et al. Anemia as a risk factor for cardiovascular disease in the atherosclerosis risk in communities (ARIC) study. J Am Coll Cardiol. 2002;40(1):27–33. doi: 10.1016/s0735-1097(02)01938-1.
  • Muzzarelli S, Pfisterer M; TIME Investigators. Anemia as independent predictor of major events in elderly patients with chronic angina. Am Heart J. 2006;152(5):991–996. doi: 10.1016/j.ahj.2006.06.014.
  • Ma J, Liu X, Qiao L, et al. Association between stent implantation and progression of nontarget lesions in a rabbit model of atherosclerosis. Circ Cardiovasc Interv. 2021;14(11):e010764.
  • Soh RY, Sia CH, Djohan AH, et al. Clinical characteristics and Long-Term outcomes of patients with differing haemoglobin levels undergoing Semi-Urgent and elective percutaneous coronary intervention in an asian population. Front Cardiovasc Med. 2022;9:687555. doi: 10.3389/fcvm.2022.687555.
  • Gao M, Zhang X, Qin L, et al. Discharge hemoglobin association with Long-Term outcomes of ST-Elevation myocardial infarction patients undergoing primary percutaneous coronary intervention. Cardiovasc Ther. 2020;2020:8647837. doi: 10.1155/2020/8647837.
  • Mortazavi BJ, Downing NS, Bucholz EM, et al. Analysis of machine learning techniques for heart failure readmissions. Circ Cardiovasc Qual Outcomes. 2016;9(6):629–640. doi: 10.1161/CIRCOUTCOMES.116.003039.
  • Mohr FW, Morice MC, Kappetein AP, et al. Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial. Lancet. 2013;381(9867):629–638. doi: 10.1016/S0140-6736(13)60141-5.
  • Manfredini R, Fabbian F, Manfredini F, et al. Takotsubo cardiomyopathy and summer: a dangerous liaison? Am Heart J. 2013;165(1):e5. doi: 10.1016/j.ahj.2012.10.011.
  • Savic-Radojevic A, Pljesa-Ercegovac M, Matic M, et al. Novel biomarkers of heart failure. Adv Clin Chem. 2017;79:93–152.
  • Weiss G, Ganz T, Goodnough LT. Anemia of inflammation. Blood. 2019;133(1):40–50. doi: 10.1182/blood-2018-06-856500.
  • Eltzschig HK, Carmeliet P. Hypoxia and inflammation. N Engl J Med. 2011;364(7):656–665. doi: 10.1056/NEJMra0910283.
  • Taylor CT, Colgan SP. Regulation of immunity and inflammation by hypoxia in immunological niches. Nat Rev Immunol. 2017;17(12):774–785. doi: 10.1038/nri.2017.103.
  • Ganz T. Anemia of inflammation. N Engl J Med. 2019;381(12):1148–1157. doi: 10.1056/NEJMra1804281.
  • Lanser L, Fuchs D, Kurz K, et al. Physiology and inflammation driven pathophysiology of iron Homeostasis-Mechanistic insights into anemia of inflammation and its treatment. Nutrients. 2021;13(11):3732. doi: 10.3390/nu13113732.
  • Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352(16):1685–1695.
  • Wolf D, Ley K. Immunity and inflammation in atherosclerosis. Circ Res. 2019;124(2):315–327. doi: 10.1161/CIRCRESAHA.118.313591.
  • Zhu Y, Xian X, Wang Z, et al. Research progress on the relationship between atherosclerosis and inflammation. Biomolecules. 2018;8(3):80. doi: 10.3390/biom8030080.
  • Hansson GK, Robertson AK, Söderberg-Nauclér C. Inflammation and atherosclerosis. Annu Rev Pathol. 2006;1:297–329. doi: 10.1146/annurev.pathol.1.110304.100100.
  • Tsigkas G, Apostolos A, Trigka A, et al. Very short versus longer dual antiplatelet treatment after coronary interventions: a systematic review and meta-analysis. Am J Cardiovasc Drugs. 2023;23(1):35–46. doi: 10.1007/s40256-022-00559-0.
  • Apostolos A, Chlorogiannis D, Vasilagkos G, et al. Safety and efficacy of shortened dual antiplatelet therapy after complex percutaneous coronary intervention: a systematic review and meta-analysis. Hellenic J Cardiol. 2023;71:33–41. doi: 10.1016/j.hjc.2023.01.005.
  • Franzone A, McFadden E, Leonardi S, et al. Ticagrelor alone versus dual antiplatelet therapy from 1 month after drug-eluting coronary stenting. J Am Coll Cardiol. 2019;74(18):2223–2234. doi: 10.1016/j.jacc.2019.08.1038.
  • Mehran R, Baber U, Sharma SK, et al. Ticagrelor with or without aspirin in High-Risk patients after PCI. N Engl J Med. 2019;381(21):2032–2042. doi: 10.1056/NEJMoa1908419.
  • Shah AD, Nicholas O, Timmis AD, et al. Threshold haemoglobin levels and the prognosis of stable coronary disease: two new cohorts and a systematic review and meta-analysis. PLoS Med. 2011;8(5):e1000439. doi: 10.1371/journal.pmed.1000439.
  • Roh DJ, Albers DJ, Magid-Bernstein J, et al. Low hemoglobin and hematoma expansion after intracerebral hemorrhage. Neurology. 2019;93(4):e372–e80. doi: 10.1212/WNL.0000000000007820.
  • Sabatine MS, Morrow DA, Giugliano RP, et al. Association of hemoglobin levels with clinical outcomes in acute coronary syndromes. Circulation. 2005;111(16):2042–2049. doi: 10.1161/01.CIR.0000162477.70955.5F.
  • Pilgrim T, Vetterli F, Kalesan B, et al. The impact of anemia on long-term clinical outcome in patients undergoing revascularization with the unrestricted use of drug-eluting stents. Circ Cardiovasc Interv. 2012;5(2):202–210. doi: 10.1161/CIRCINTERVENTIONS.111.965749.
  • Kunadian V, Mehran R, Lincoff AM, et al. Effect of anemia on frequency of short- and long-term clinical events in acute coronary syndromes (from the acute catheterization and urgent intervention triage strategy trial). Am J Cardiol. 2014;114(12):1823–1829. doi: 10.1016/j.amjcard.2014.09.023.
  • Matsue Y, Matsumura A, Abe M, et al. Prognostic implications of chronic kidney disease and anemia after percutaneous coronary intervention in acute myocardial infarction patients. Heart Vessels. 2013;28(1):19–26. doi: 10.1007/s00380-011-0209-2.
  • Babitt JL, Lin HY. Mechanisms of anemia in CKD. J Am Soc Nephrol. 2012;23(10):1631–1634. doi: 10.1681/ASN.2011111078.
  • Zhang F, Lu Z, Wang F. Advances in the pathogenesis and prevention of contrast-induced nephropathy. Life Sci. 2020;259:118379. doi: 10.1016/j.lfs.2020.118379.
  • Ozbeyaz NB, Gokalp G, Algul E, et al. H(2)FPEF score and Contrast-Induced nephropathy in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Angiology. 2023;74(2):181–188. doi: 10.1177/00033197221099425.
  • Özbeyaz NB, Gökalp G, Aydınyılmaz F, et al. Hypomagnesemia and the risk of contrast-induced nephropathy in patients undergoing elective coronary angiography. Turkish J Clin Lab. 2022. doi: 10.18663/tjcl.1183898.
  • McGill JB, Bell DS. Anemia and the role of erythropoietin in diabetes. J Diabetes Complicat. 2006;20(4):262–272. doi: 10.1016/j.jdiacomp.2005.08.001.
  • Aydınyılmaz F, Sunman H, Algül E, et al. The effect of ticagrelor and clopidogrel on angiographic parameters according to diabetic status in patients with ST elevation myocardial infarction. Russ J Cardiol. 2022;27(9):5021. doi: 10.15829/1560-4071-2022-5021.